Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$21.26
-9.9%
$24.36
$13.40
$26.65
$3.98B0.751.86 million shs8.44 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$193.28
-0.4%
$188.87
$118.03
$208.16
$11.95B0.39384,989 shs200,394 shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$14.42
-0.6%
$14.33
$12.26
$16.19
$12.11B0.32739,428 shs861,298 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$20.50
+7.0%
$24.50
$15.55
$36.91
$14.23B-1.025.44 million shs5.65 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-3.79%-1.50%-8.31%+4.89%+44.87%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-1.24%-1.65%-0.16%+12.13%+32.32%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-0.84%-1.79%-0.33%-6.66%-8.85%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+0.26%+5.68%-26.91%-9.97%-12.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$21.26
-9.9%
$24.36
$13.40
$26.65
$3.98B0.751.86 million shs8.44 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$193.28
-0.4%
$188.87
$118.03
$208.16
$11.95B0.39384,989 shs200,394 shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$14.42
-0.6%
$14.33
$12.26
$16.19
$12.11B0.32739,428 shs861,298 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$20.50
+7.0%
$24.50
$15.55
$36.91
$14.23B-1.025.44 million shs5.65 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-3.79%-1.50%-8.31%+4.89%+44.87%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-1.24%-1.65%-0.16%+12.13%+32.32%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-0.84%-1.79%-0.33%-6.66%-8.85%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+0.26%+5.68%-26.91%-9.97%-12.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.65
Moderate Buy$29.5338.90% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$244.3626.43% Upside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.80
Moderate Buy$16.9517.55% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.56
Moderate Buy$31.8755.45% Upside

Current Analyst Ratings Breakdown

Latest ACAD, SMMT, RDY, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$30.00 ➝ $28.00
9/17/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageUnderweight$13.00
9/16/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Summit Redstone
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$13.00
9/16/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageUnderweight$13.00
9/16/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$50.00
9/11/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/11/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$35.00 ➝ $39.00
9/9/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$36.00 ➝ $39.00
9/8/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/8/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$50.00
9/3/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$40.00
(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.02B3.52$0.64 per share33.48$4.40 per share4.83
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$393.54M30.26N/AN/A($1.88) per share-102.81
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.81B3.16$1.03 per share14.05$4.73 per share3.05
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$700K21,754.89N/AN/A$0.53 per share38.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$226.45M$1.3315.9827.975.9821.80%14.69%9.41%11/5/2025 (Estimated)
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$5.16N/A805.33N/A-54.94%N/A-24.31%11/13/2025 (Estimated)
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$663M$0.6621.8517.595.8616.99%17.25%11.63%11/4/2025 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$221.32M-$1.010.00N/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)

Latest ACAD, SMMT, RDY, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10-$0.76-$0.66-$0.76N/AN/A
8/7/2025Q2 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million
8/6/2025Q2 2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.14$0.16+$0.02$0.16$263.07 million$264.57 million
7/23/2025Q1 25/26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.18$0.20+$0.02$0.20$88.27 billion$988.82 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.070.49%N/A10.61%N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A

Latest ACAD, SMMT, RDY, and ASND Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/30/2025
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
annual$0.09150.623832253665189%7/25/20257/10/20258/6/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
2.91
2.83
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.02
0.69
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.01
1.89
1.36
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
5.13
5.13

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510168.71 million124.00 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,01761.62 million36.97 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,811834.92 million818.23 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110742.85 million112.17 millionOptionable

Recent News About These Companies

Summit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Barclays
HC Wainwright Reaffirms Buy Rating for Summit Therapeutics (NASDAQ:SMMT)
Summit Therapeutics Inc. Investigated by the Portnoy Law Firm
Insiders Are Aggressively Buying These 5 Stocks

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.26 -2.34 (-9.92%)
Closing price 04:00 PM Eastern
Extended Trading
$21.36 +0.09 (+0.45%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$193.28 -0.70 (-0.36%)
Closing price 04:00 PM Eastern
Extended Trading
$193.30 +0.03 (+0.01%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$14.42 -0.09 (-0.62%)
Closing price 03:59 PM Eastern
Extended Trading
$14.44 +0.02 (+0.10%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$20.50 +1.35 (+7.05%)
Closing price 04:00 PM Eastern
Extended Trading
$20.38 -0.13 (-0.61%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.